(Q37364832)

19 August 2017

1 reference

title

Levodopa therapeutics for Parkinson's disease: new developments (English)

1 reference

19 August 2017

1 reference

1 reference

Peter A LeWitt

1

1 reference

19 August 2017

publication date

1 January 2009

1 reference

Parkinsonism and Related Disorders

19 August 2017

published in

1 reference

19 August 2017

volume

15 Suppl 1

1 reference

19 August 2017

page(s)

S31-4

1 reference

Accuracy of acute levodopa challenge for clinical prediction of sustained long-term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Dopamine miracle: from brain homogenate to dopamine replacement

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Aromatic Amino Acids and Modification of Parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Modification of Parkinsonism--chronic treatment with L-dopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Pharmacokinetics of Levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Effect of supplemental carbidopa on bioavailability of L-dopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

L-dopa decarboxylation in chronically treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Changes in neostriatal dopamine concentrations in response to levodopa infusions

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

The long-duration response to L-dopa in the treatment of early PD.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Levodopa in the treatment of Parkinson's disease: current controversies

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

L-DOPA does not enhance hydroxyl radical formation in the nigrostriatal dopamine system of rats with a unilateral 6-hydroxydopamine lesion

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Levodopa and the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Effect of late initiation of levodopa treatment in patients with long-standing Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Restoration of the striatal dopamine synthesis for Parkinson's disease: viral vector-mediated enzyme replacement strategy.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

L-3,4-Dihydroxyphenylalanine as a neurotransmitter candidate in the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus).

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

"Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970009-4

7 January 2021

10.1016/S1353-8020(09)70009-4

Identifiers

DOI

1 reference

19 August 2017

1 reference